Study	Reason for exclusion
Bower 2012	Wrong outcomes. Did not investigate AIMSS
Brown 2015	Wrong patient population. No AI subgroup
Cantarero‐Villanueva 2013a	Wrong study design. Not an RCT
Cantarero‐Villanueva 2013b	Wrong outcomes. Did not investigate AIMSS. No AI subgroup
DeNysschen 2014	Wrong study design. Not an RCT
Desbiens 2017	Wrong outcome. Did not investigate AIMSS
Djuric 2011	Wrong patient population. No AI subgroup
Galantino 2013	Wrong study design. Not an RCT
Galiano‐Castillo 2017	Wrong patient population. No AI subgroup
Goodwin 2014	Wrong outcomes. Did not investigate AIMSS. Unable to determine if population had AIMSS at baseline
Harrigan 2016	Wrong outcomes. Did not investigate AIMSS
Kiecolt‐Glaser 2014	Wrong outcomes. Did not investigate AIMSS
Knobf 2017	Wrong patient population. Not specific to BC population
Lash 2011	Wrong study design. Not an RCT
Ligibel 2008	Wrong patient population. Majority received tamoxifen
Ligibel 2011	Wrong outcomes. Did not investigate AIMSS. Substudy of Goodwin 2014
Nikander 2012	Wrong patient population. No AI subgroup
Nyrop 2016	Wrong study design. No intervention
Pakiz 2016	Wrong study design. No intervention
Paulo 2019	Wrong outcomes. Did not investigate AIMSS.
Payne 2008	Wrong outcomes. Did not investigate AIMSS.
Penttinen 2009	Wrong outcomes. Did not investigate AIMSS.
Peppone 2012	Wrong patient population. Included women on tamoxifen
Peppone 2015	Wrong patient population. Included women on tamoxifen
Pruthi 2012	Wrong patient population. No AI subgroup
Reeves 2017	Wrong outcomes. Did not investigate AIMSS
Rogers 2009	Wrong patient population. No AI subgroup data available
Rogers 2009a	Wrong outcomes. Baseline AIMSS not investigated
Segal 2011	Wrong outcomes. Did not investigate AIMSS
Winkels 2017	Wrong patient population. No AI subgroup
Winters‐Stone 2012	Wrong patient population. No pre‐defined AIMSS subgroup

AI: aromatase inhibitor; AIMSS: aromatase inhibitor‐induced musculoskeletal symptoms; BC: breast cancer; RCT: randomised controlled trial